Serum concentrations (ng/ml) of anti-ROR1 autoantibodies in chronic lymphocytic leukemia (CLL) patients and controls, as measured by ELISA against the full-length ROR1 protein (OriGene TP314967). Solid circles: non-progressive CLL; crosses: progressive CLL; blank circles: control donors. Dotted line represents mean+2SD of controls. *** p < 0.0001. Figure cited from PLoS ONE, PMID: 26562161
Anti-ROR1 autoantibodies from three non-progressive (NP) and three progressive (P) chronic lymphocytic leukemia patients were analyzed in Western blot using the recombinant full-length ROR1 protein (OriGene TP314967). A goat anti-ROR1 antibody and an isotype control MAb served as positive and negative controls, respectively. Figure cited from PLoS ONE, PMID: 26562161
Cytotoxicity (%) of leukemic cells induced by the serum IgG fractions from five non-progressive (circles) and five progressive (crosses) chronic lymphocytic leukemia patients before and after the adsorption of sera with the recombinant full-length ROR1 protein (OriGene TP314967). *** p < 0.0001. Figure cited from PLoS ONE, PMID: 26562161
Coomassie blue staining of purified ROR1 protein (Cat# TP314967). The protein was produced from HEK293T cells transfected with ROR1 cDNA clone (Cat# RC214967) using MegaTran 2.0 (Cat# TT210002).
Supplier Page from OriGene Technologies for ROR1 (NM_005012) Human Recombinant Protein